Drug
Iov 5001
Iov 5001: highest development phase Phase 1/2, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| IOV-5001 NCT07743723 | Phase 1/2 | Advanced Solid Tumors |
Latest
No recent events.
Follow Iov 5001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.